SCHEMBL2503391

SCHEMBL2503391

O=C(O)CC(CC1CC1)c1cccc(O)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 4/20 0.44
OPRD1 P41143 3/20 0.44
GABBR2 O75899 1/20 0.41
GABBR1 Q9UBS5 1/20 0.41
KYNU Q16719 1/20 0.41
FFAR1 O14842 2/20 0.41
ITGB3 P05106 2/20 0.39
ITGAV P06756 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CHRNA7 P36544 1/20 0.37
F10 P00742 1/20 0.37
ITGB5 P18084 1/20 0.36
DRD2 P14416 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9577580 0.84 GABBR2 (0.58) GABBR2GABBR1FFAR1MEN1KMT2A
SCHEMBL5858131 0.84 GABBR2 (0.52) GABBR2GABBR1KYNUITGB3ITGAV
SCHEMBL12192906 0.81 OPRD1 (0.45) OPRK1OPRD1LMNAF10
SCHEMBL27830800 0.81 OPRD1 (0.45) OPRK1OPRD1LMNAF10
SCHEMBL12192903 0.81 OPRD1 (0.45) OPRK1OPRD1LMNAF10
SCHEMBL12192919 0.81 FFAR1 (0.54) FFAR1LMNA
SCHEMBL12192914 0.81 FFAR1 (0.54) FFAR1LMNA
SCHEMBL1634407 0.78 GABBR2 (0.46) GABBR2GABBR1KYNUFFAR1LMNA
SCHEMBL2499542 0.78 GABBR2 (0.46) GABBR2GABBR1KYNUFFAR1LMNA
SCHEMBL2500898 0.78 GABBR2 (0.46) GABBR2GABBR1KYNUFFAR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030354-B2 2-(5,5-Dimethylcyclopent-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane; metabolic disorders such as type II diabetes AMGEN INC. (US) 2011-10-04 US disclosed
EP-2205548-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS Amgen, Inc (US) 2010-07-14 EP disclosed
US-20090137561-A1 Substituted biphenyl GPR40 modulators AMGEN INC. (US) 2009-05-28 US disclosed
WO-2009048527-A1 SUBSTITUTED BIPHENYL GPR40 MODULATORS AMGEN INC. (US) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137561-A1 Substituted biphenyl GPR40 modulators GPR119, GPR65, GPR55 OPRK1 557/4885OPRD1 852/4885GABBR2 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.